注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
榮昌生物製藥(煙台)股份有限公司是一家主要從事創新型生物藥研發和製造的中國公司。該公司專注於抗體藥物偶聯物(ADC)、抗體融合蛋白、單克隆抗體及雙特異性抗體等治療性抗體藥物的發現、開發與商業化。該公司的主要產品包括泰它西普(RC18)、維迪西妥單抗(RC48)和雙靶點融合蛋白(RC28)。該公司的產品主要應用於治療自身免疫疾病、腫瘤和眼科等重大疾病。該公司主要在國內市場開展業務。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Xiaodi Su | 35 | 2020 | Non-Executive Director |
Guangke Ren | 48 | 2020 | Chairman of the Supervisory Committee |
Lorne Alan Babiuk | 75 | 2020 | Member of Scientific Advisory Board |
Yupeng Li | 38 | 2020 | Supervisor |
Weidong Wang | 62 | 2013 | Co-Founder & Executive Chairman |
Zhuanglin Li | 46 | 2020 | Supervisor |
Yunjin Chen | 36 | 2022 | Independent Non-Executive Director |
Gang Pei | - | - | Member of Scientific Advisory Board |
Xianjing Hao | 55 | 2020 | Independent Non-Executive Director |
Liqiang Wang | 51 | 2020 | Non-Executive Director |
Lan Ma | 64 | 2021 | Independent Non-Executive Director |
Marsha A. Moses | - | - | Member of Scientific Advisory Board |
Ruyi He | 62 | 2020 | Chief Medical Officer, Head of Clinical Research, Member of Scientific Adv. Board & Executive Dir. |
Jian Lin | 67 | 2008 | Executive Director |
Jianmin Fang | 61 | 2008 | Co-Founder, CEO,Member of Scientific Advisory Board & Executive Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核